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Abstract
We analyzed diversity of mRNA produced as a result of alternative splicing in order to evaluate gene
function. First, we predicted the number of human genes transcribed into protein-coding mRNAs by
using the sequence information of full-length cDNAs and 50-ESTs and obtained 23 241 of such human
genes. Next, using these genes, we analyzed the mRNA diversity and consequently sequenced and ident-
iﬁed 11 769 human full-length cDNAs whose predicted open reading frames were different from other
known full-length cDNAs. Especially, 30% of the cDNAs we identiﬁed contained variation in the transcrip-
tion start site (TSS). Our analysis, which particularly focused on multiple variable ﬁrst exons (FEVs)
formed due to the alternative utilization of TSSs, led to the identiﬁcation of 261 FEVs expressed in the
tissue-speciﬁc manner. Quantiﬁcation of the expression proﬁles of 13 genes by real-time PCR analysis
further conﬁrmed the tissue-speciﬁc expression of FEVs, e.g. OXR1 had speciﬁc TSS in brain and tumor
tissues, and so on. Finally, based on the results of our mRNA diversity analysis, we have created the FLJ
Human cDNA Database. From our result, it has been understood mechanisms that one gene produces suit-
able protein-coding transcripts responding to the situation and the environment.
Key words: full-length cDNA; alternative splicing; alternative transcription start site; mRNA diversity; tissue-
speciﬁc expression
1. Introduction
One of the most interesting ﬁndings revealed by the
Human Genome Project is that the human genome
contains only 20 000–25 000 protein-coding
genes.
1 This number is unexpectedly too small. To
explain this unexpected result and to understand func-
tionsofgenes,itisnecessarytoanalyzemRNA diversity.
Biologically, multiple transcripts can be generated
from a single gene by alternative splicing (AS).
According to several reports on genome research, AS
occurs in 30–60% of human genes.
2–5 It has been
reported that AS of a single gene could produce tran-
scripts coding for multiple proteins, each exhibiting
different biochemical properties including binding,
intracellular localization and regulation of enzymatic
activities.
6 AS is also of interest to the pharmaceutical
research because unwanted AS of genes could lead to
various genetic diseases and cancers.
7 We have par-
ticularly focused on the analysis of AS patterns that
are produce by utilizing alternative transcription
start sites (TSSs). Indeed, multiple transcripts were
produced from a gene by utilizing variable TSSs.
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TSSs, was shown to produce different transcripts;
10
similarly, UGTs (UDP-glucuronosyltransferases),
which contained more than 10 TSSs.
11 From these
ﬁndings, it is clear that to elucidate gene function,
we have to further our knowledge on and understand-
ing of all transcripts made from each gene, particu-
larly those of the protein-coding transcripts.
However, identiﬁcation of all protein-coding tran-
scripts have so far been difﬁcult due to the fact that
a large number of EST data accumulated in the data-
bases are 3’-EST data, which were obtained by
sequencing cDNAs from the polyA-end. Thus, even
though sequences of a large number of mRNAs are
already known, our understanding of these mRNAs
remained incomplete because of the fragmentary
nature and 30-end bias of their sequences. Because
of the lack of sequence information, it has been difﬁ-
cult to predict TSSs and to identify all the open
reading frame (ORF) regions. Although the use of
next generation sequencer helped in making
advances in analyzing TSSs, it still remains extremely
difﬁcult to evaluate diversities of mRNAs transcribed
by each gene because of their accumulation of
short-length sequences (less than 50 bases) of cDNA
clones.
12,13
We sequenced  55 000 human full-length cDNAs,
including 11 769 newly identiﬁed cDNAs described in
this paper, and also obtained  1.45 million 5’-end-
one-pass sequences (5’-EST).
14–17 We believe that
these cDNA sequences are very useful in analyzing
the diversity of protein-coding transcripts and would
deﬁnitely contribute to our understanding of mRNA.
First, our cDNA clones were isolated from full-length
human cDNA libraries constructed by an optimized
oligo-capping method, and therefore by utilizing
their sequence information, we were able to identify
the TSS with 90% or better accuracy.
14,18–20 Thus,
we could easily and accurately identify TSSs of even
low-expressing genes, for which up until now it
required comparison of a large amount of data.
17
Second, our 50-EST data contained, on the average,
sequence information of  500 bases/cDNA clone,
which covered two or more exons. Since the average
length of the 5’-untranslated region is believed to be
125 bases,
21 it was possible to predict ORF regions
using our 5’-EST data. Finally, the most important
point is that all of our resources were obtained from
the full-length cDNAs, including the TSS and the
polyA site. Moreover, we could obtain various ﬁndings
on protein expression from our full-length cDNAs.
16
These ﬁndings could not be obtained from sequences
of short mRNA fragments. Since AS of genes could
potentially create a large number of protein-coding
transcripts, analyzing full-length cDNAs might be
immensely valuable in understanding gene function.
Here, we report on our analysis of 11 769 full-
length cDNAs, which were identiﬁed from our full-
length cDNA libraries, and contained ORFs as a
result of AS. We also present our analysis on the
splice patterns and expression proﬁles of the ident-
iﬁed cDNAs to explore the correlation between the
mRNA diversity and gene function. Furthermore, we
describe 261 full-length cDNAs with unique TSSs
known as multiple variable ﬁrst exon (FEV) and
report on their expression proﬁles. Finally, we
report establishing the FLJ Human cDNA Database
based on the results of our analysis of the variable
protein-coding transcripts generated from each gene
by AS.
2. Materials and methods
2.1. Construction of full-length cDNA libraries
Most total RNAs isolated from various tissues and
cells were purchased from Clontech and Ambion.
Cells were cultured following established protocol,
and cytoplasmic total RNAs were extracted from
these cultured cells following a standard RNA puriﬁ-
cation method. The list of total RNAs used in this
study was shown in Supplementary Table S1. We con-
structed cDNA libraries from total RNAs by an opti-
mized oligo-capping method (detailed method for
the optimized oligo-capping is provided in the
Supplementary Method 1).
18,19 Brieﬂy, total RNAs
were treated with bacteria alkaline phosphatase
(TaKaRa) and tobacco acid pyrophosphatase. After
that, total RNAs were ligated to the oligo-RNA using
the RNA ligase (TaKaRa). Oligo-capped polyA(þ)
RNAs were then isolated oligo-dT columns. The ﬁrst-
strand cDNAs were synthesized using the Superscript
II reverse transcriptase (Invitrogen), the synthesized
cDNAs were ampliﬁed using the Gene Amp XL PCR
kit (ABI) and the ampliﬁed product was digested
with the restriction enzyme SﬁI. Fragments longer
than 2 kb were selected and puriﬁed by agarose gel
electrophoresis and cloned into the DraIII-digested
pME18SFL3 vector following the standard methods.
The 50-end-one-pass sequences of cloned cDNAs
were analyzed using the ABI 377 and 3700 sequen-
cers (ABI). The 5’-end fullness rate of the constructed
oligo-capped cDNA libraries was evaluated as
described previously,
22,23 and the detailed method
for determining the 5’-end fullness rate is provided
in the Supplementary Method 2.
2.2. Genome mapping and clustering
The 50- and 30-ends of cDNA sequences and the full-
length cDNA sequences (Supplementary Table S2)
were mapped onto the human genome (UCSC hg
18 NCBI Build 36.1). Possible local alignments
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identiﬁed by using the NCBI Mega BLAST program
(ftp://ftp.ncbi.nih.gov/blast/). For each cDNA, best
mapping of the sequence was determined from
these local alignments using a dynamic programming
technique that optimized the identity, coverage and
topology of exons. The joining portions of consecutive
local alignments were reﬁned so as to restore the con-
sensus sequence in the canonical splice sites. On the
basis of the mapping results clustering of cDNA
sequences were performed as follows: two cDNA
sequences were grouped into the same cluster if
their mapped positions shared at least one base on
the genome. In general, each cluster corresponded
to a single gene locus.
2.3. Identiﬁcation of alternatively spliced variants
of mRNAs
On the basis of the results of genome mapping and
clustering analysis, ESTs that had different regions
compared with known full-length cDNAs by AS were
selected by Intris, a viewer for cDNA-genome align-
ments used for analysis of splicing variants and
expression proﬁles.
24 To exclude the cDNA fragments
derived from the immature mRNA and genomic
DNA, reliability of mRNA was evaluated by using not
only the human EST data but also the data conserved
from other animals (Phastcons; obtained from UCSC
Genome Browser). We predicted the ORF regions
from the 5’-end sequences of full-length cDNAs on
selected ESTs by using ATGpr (http://ﬂj.lifesciencedb.
jp/top/).
25 Next, we excluded those ESTs from the
selected analytical targets when the predicted ORF
regions of the selected ESTs were the same as the
ORF regions of known full-length cDNAs. In addition,
even if the predicted ORF regions were different
from the ORF regions of known full-length cDNAs,
we excluded cDNA clones containing extremely short
ORF regions (mostly 60 amino acids or less) com-
pared with the other full-length cDNAs that mapped
in the same locus of the human genome. The selected
cDNAs were further sequenced by primer walking
method using an ABI3700 sequencer (ABI) to obtain
information on 500 additional bases, and the ORF
regions were predicted again by using the ATGpr.
25
We also evaluated the predicted ORF regions by
using TRis,
26 translated region inspector, and exam-
ined their novelty of amino acid sequences by using
ALVISION,
27 aligns two cDNA sequences that are spli-
cing variants allowing large gaps. When the reliability
of the predicted ORF region was insufﬁcient, we
excluded it from our list of analytical targets. When
the predicted ORF regions of the selected cDNAs
were judged reliable and different from those of the
known full-length cDNAs, we then sequenced the
full-length cDNA clone all the way up to the stop
codon. Consequently, we completely sequenced
11 769 of full-length FLJ cDNAs and analyzed their
tissue-speciﬁc expression. A detailed method for the
analysis of the tissue-speciﬁc expression of the
cDNAs is provided in the Supplementary Method 3.
We have also constructed the FLJ Human cDNA
Database (http://ﬂj.lifesciencedb.jp) that contained
these sequence information. A detailed method for
the analysis of AS by using the information available
in the FLJ Human cDNA Database is provided in the
Supplementary Method 4. Sequences of 11 769 of
our full-length cDNAs were also deposited in the
DDBJ/GenBank/EMBL databases (AK293122–
AK304890).
2.4. Functional analysis of full-length cDNAs in silico
Sequences of cDNAs were analyzed for the signal
sequences, trans-membrane domains and motifs
in the encoded proteins by using Signal P ver. 3.0
(http://www.cbs.dtu.dk/services/SignalP/), SOSUI ver.
1.5 (Mitsui Knowledge Industry) and Pfam 19.0
(November 2005; http://pfam.sanger.ac.uk/),
respectively. We obtained information on motifs
showing E-values of e-30 or more from the Pfam
analysis, and based on these results, we then categor-
ized each cDNA and the corresponding gene accord-
ing to its gene ontology (GO) (http://www.
geneontology.org/) classiﬁcation by using InterPro
(http://www.ebi.ac.uk/interpro/).
2.5. Quantitative real-time PCR analysis
Total RNAs derived from various tissues were pur-
chased from Clontech, Ambion and STRATAGENE
(listed in Supplementary Table S4). From 10 mgo f
each total RNA, ﬁrst-strand cDNAs were synthesized
using random primers and the Superscript III reverse
transcriptase (Invitrogen) following the manufac-
turer’s instructions. Real-time PCR was performed
using TaqMan Universal Master Mix (ABI) or SYBR
Master Mix (ABI) on an ABI Fast7500 System (ABI)
according to the manufacturer’s instructions.
Approximately 300 ng of template cDNAs was used
in each PCR reaction. Probes and primers were
designed using the Primer Express3.0 (ABI) (refer to
Supplementary Table S5 for the list of primers). The
expression levels of genes were normalized with
respect to that of the human GAPDH, and expression
values of individual genes were calculated by compar-
ing their Ct values to that of the control using the RQ
software (ABI). The expression levels of genes were
represented in log10 base. Samples were run in dupli-
cates and the data shown are the average of two
experiments.
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3.1. Identiﬁcation of human genes
ItisknownthatAScouldproducemRNAdiversity.
2–6
However, to analyze the mRNA diversity, it is necessary
to identify human genes (i.e. the genome loci from
where the protein-coding mRNAs are transcribed).
We obtained 1.45 million human full-length cDNAs
and sequenced their 5’-ends. We previously selected
 30 000 cDNAs from these full-length cDNAs based
on the novelty analysis, and completely sequenced
them.
14–16 Later, we also selected  25 000 cDNAs
based on the mRNA diversity and also sequenced
them completely. In our quest to identify human
genes, we used, for our analysis, the sequence infor-
mation on these 55 000 full-length human cDNAs
including 11 769 cDNAs reported in this paper
(Supplementary Table S2). Furthermore, for the analy-
sis, we not only used our own data but also data from
52 000 full-length human cDNA sequences available
from the public databases, 30 000 human RefSeq
(NCBI Reference Sequences; http://www.ncbi.nlm.nih
.gov/RefSeq/) and 48 000 Ensembl, human gene
transcripts (http://www.ensembl.org/index.html). In
addition, we used EST sequences obtained by us and
from other public databases (Supplementary Table
S2). All the sequence data we collected were mapped
onto the human genome and clustered. We then
examined reliability of each full-length cDNAs by
Intris
24 using sequences of all full-length cDNAs and
ESTs mapped on the same locus of the genome, and
based on this analysis, we selected only the reliable
cDNAs for the gene identiﬁcation analysis. We deter-
mined the genome locus of each one of the selected
reliable cDNA and manually checked them one by
one to identify the corresponding gene. As a result,
we identiﬁed 23 241 human genes from this analysis
(Fig.1A).Eachgeneclusterwasclassiﬁedintothreecat-
egories based on the reliability scores. The number of
genes in the high reliability category (high category)
were 16 754. Sequences of cDNAs belonging to the
high-categorygroupwerefoundtobealreadyanalyzed
because the genome locus was covered by sequence
information available from the three types of data-
bases, the human full-length cDNAs, RefSeq and
Ensembl. It accounted for 72% of the total number of
genes. The number of genes with intermediate
reliability (medium category) was 2854. As for the
medium-category group, the genome locus was
covered by sequence information available from only
the human full-length cDNAs or from two out of
three of the above-mentioned databases. The
number of genes with low reliability (low category)
were 3633. As for the low-category group, the gene
locus was covered by sequence information available
only from the RefSeq or the Ensembl.
Figure 1. Clustering of human cDNA sequences. (A) Estimation of the number of human genes from full-length cDNAs and ESTs. Outline of
our gene prediction method from the human full-length cDNAs and ESTs mapped to human genome is schematically shown. For each
one of the predicted genes, classiﬁcation reliability was evaluated manually. (B) Cover rate of FLJ EST sequences and (C) cover rate of FLJ
full-length sequenced cDNAs. Results of reliability analysis according to the category based on the cover rates of 1.45 million of ESTs (B)
and 55 000 full-length cDNAs (C).
374 Identiﬁcation and Functional Analyses of Full-length Human cDNAs [Vol. 16,To further assess these reliabilities, we next calcu-
lated the cover rate of genes using our cDNAs. First,
the cover rate was calculated using our 1.45 million
FLJ ESTs, and we found a positive correlation
between these reliabilities and the cover rate of FLJ
ESTs (Fig. 1B). Next, we calculated the cover rate of
genes using our 55 000 FLJ human full-length cDNA
sequences. In this case, we also found a positive corre-
lation between the reliability and the cover rate
similar to that was observed for the ESTs (Fig. 1C).
Thus, we were able to verify reliability irrespective of
whether we used the sequences of our ESTs or full-
length cDNAs in the analysis.
3.2. Analysis of AS and functional classiﬁcation
of sequenced full-length cDNAs by GO
We selected 25 000 full-length cDNAs from among
the identiﬁed genes by focusing our attention on AS
and subsequently sequenced them. In addition, from
these cDNAs, we selected 11 769 of human full-
length cDNAs in which the ORF regions were pre-
dicted to be different from the known full-length
cDNAs, and then classiﬁed them by GO according to
their predicted functions. First, ESTs exhibiting a
different splicing pattern than the known full-length
cDNAs were selected and were completely sequenced.
From the sequence analysis, we were able to predict
the ORF regions in only 30% of them (results not
shown). Interestingly, a number of cDNA, for which
we were unable to predict the ORF region, were
thought to produced by AS. But, because our target
was to be able to predict the function of the gene
from the sequence of its transcript, it was necessary
to select protein-coding transcripts efﬁciently. It is dif-
ﬁcult to predict the ORF region correctly from the EST
sequences lacking the TSS. However, our 5’-EST
sequences not only contained the TSS but also con-
tained sequence information on an average of 500
bases from the TSS. Therefore, we were able to cor-
rectly predict the ORF regions of our 5’-EST by using
ATGpr.
25 As a result, the number of clones containing
unpredictable ORF regions decreased to  10%.
Moreover, by using the tools such as TRins
26 for
inspecting the translated region and ALVISION
27 for
evaluating the novelty of amino acid sequences, we
succeeded in identifying the ORF regions with high
accuracy. Consequently, we obtained 11 769 of
human full-length cDNAs in which the ORF regions
were predicted to be different from the known full-
length cDNAs (Supplementary Table S3). Ninety-six
percent of these cDNAs-encoded proteins which dif-
fered in at least 10 amino acids from those encoded
by their respective known full-length cDNAs, mainly
because we selected them based on their altered
ORF regions as a result of AS. These full-length
cDNAs covered 7025 of 23 241 genes that we had
originally identiﬁed.
Once it was established that human genes could
produce multiple protein-coding transcripts, it was
important to analyze their putative functions. The
GO classiﬁcation analysis was performed for all
11 769 our full-length cDNAs using Pfam, and their
predicted functions, obtained from this analysis, are
summarized in Table 1. The classiﬁcation results
revealed that a large number of our cDNA clones
were listed under the GO molecular function cat-
egories ‘nucleotide binding’, ‘nucleic acid binding’,
‘protein binding’, ‘hydrolase activity’, ‘transferase
activity’ and ‘oxidoreductase activity’. Because
11 769 of our full-length cDNAs had ORF regions
different from those of the known full-length cDNAs,
we also analyzed their functions by predicting
domains and motifs using Pfam, SOSUI and SignalP
(Supplementary Table S3). Consequently, we discov-
ered full-length cDNAs that encoded proteins with
altered functional domains and signal sequences as
a result of AS.
3.3. Classiﬁcation of splicing patterns of full-length
cDNAs
Up until now, majority of the ESTs entered in the
public databases were 3’-EST. We succeeded in con-
structing full-length cDNA libraries efﬁciently by
using the optimized oligo-capping method and
obtained  1.4 million 5’-ESTs of full-length cDNAs
constructed by this method.
18,19 Our 5’-EST
sequences were especially useful for the analysis of
TSSs because 90% or more of our cDNAs contained
the TSSs. We analyzed the splicing patterns of the
11 769 cDNAs by using the 5’-EST sequence data
(Fig. 2). Results of this analysis revealed that 3403
cDNAs, which correspond to  30% of all cDNAs,
were transcribed using alternative TSSs (Type A), and
thus, the predicted proteins contained new amino
acid sequences at their N-terminal ends. In addition,
1962 cDNAs in Type A (designated as Type A1) con-
tained FEV, due to transcripts originating from a TSS
that was previously ignored because it was mapped
in an intron region of the genome or transcripts orig-
inating from a TSS that was mapped upstream from
the one that was analyzed before. Taken together,
these results led to the discovery of new exons. We
analyzed expression proﬁles of the genes containing
multiple TSSs and discovered that the same gene
could code for proteins with diverse function in differ-
ent tissues by the proper utilization of alternative
TSS. There were 8277 cDNAs (i.e.  70% of all the
full-length cDNAs) that were transcribed from the pre-
viously identiﬁed TSSs, but contained different ORF
region because of AS; they were designated as Type
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lot of Type B cDNAs were predicted to contain N-term-
inal sequences different from those of the known
cDNAs, except for a portion of cDNAs which were
either selected by PCR or found during sequencing
analysis. To assess whether AS or use of alternative
TSS could alter the function of the predicted protein,
we compared the GO functional categories of the
Type A and Type B (Table 2). Our results showed that
majority of the Type A belonged mainly to the GO
molecular function categories of ‘neurotransmitter
binding’, ‘enzyme activator activity’, ‘cyclase activity’,
‘ATPase activity, coupled to movement of substances’
and ‘GTPase regulator activity’. Thus, by using our
5’-EST data, a lot of valuable information were
obtained regarding the diversity of TSS and amino
acid sequences at the N-terminal ends of proteins.
However, since only a portion of the full-length
cDNAs was selected for this analysis, information on
sequence diversity in regions beyond 500 bases from
the TSSs were not obtained. We believe that there
are additional alternately spliced transcripts which
remained to be analyzed in the future studies.
Table 1. Functional classiﬁcation of the 11 769 full-length cDNAs
based on the molecular function hierarchy of GO
Functional categorization (GO: molecular
function)
Number of
matched cDNAs
Binding
Nucleotide binding 681
Nucleic acid binding 341
Protein binding 202
Ion binding 149
Lipid binding 28
Tetrapyrrole binding 27
Neurotransmitter binding 24
Carbohydrate binding 22
Other bindings 57
Catalytic activity
Hydrolase activity 506
Transferase activity 479
Oxidoreductase activity 207
Ligase activity 85
Lyase activity 47
Helicase activity 38
Isomerase activity 26
Other catalytic activities 106
Enzyme regulator activity
GTPase regulator activity 45
Enzyme inhibitor activity 44
Other enzyme regulator activities 21
Motor activity
Microtubule motor activity 24
Other motor activities 20
Signal transducer activity
Receptor activity 124
Receptor binding 25
Other signal transducer activities 40
Structural molecule activity
Structural constituent of ribosome 25
Other structural molecule activities 56
Transcription regulator activity
Transcription factor activity 138
Other transcription regulator activities 39
Translation regulator activity
Translation factor activity, nucleic acid
binding
25
Transporter activity
Ion transporter activity 169
Carrier activity 90
Channel or pore class transporter activity 79
ATPase activity, coupled to movement of
substances
39
Continued
Table 1. Continued
Functional categorization (GO: molecular
function)
Number of
matched cDNAs
Other transporter activities 131
Others 2
Molecular function unknown 45
If a protein was predicted to belong to two or more cat-
egories, all categories were included for counting.
Figure 2. Classiﬁcations of the 11 769 full-length cDNAs based on
splicing patterns. The 11 769 human full-length cDNAs were
classiﬁed according to their TSS utilization. Type A: these
cDNAs were derived from transcripts which were generated
utilizing a TSS different than the previously analyzed TSS of the
gene. Type A1: cDNAs contained a sequence variation known
as FEV. Type A2: this class of cDNAs did not have the FEV
feature. Type B: these cDNAs were derived from transcripts
that were generated utilizing the same TSS as the previously
analyzed TSS, but were found to be alternatively spliced. We
could not classify 89 cDNAs because they coded for newly
identiﬁed proteins.
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We analyzed expression of genes producing multiple
protein-coding transcripts by AS and found that many
of these transcripts were expressed in speciﬁc tissues
or cells, suggesting that the genes likely use this diver-
sity according to the need and situation. We next ana-
lyzed expression proﬁles of 10 069 cDNAs, which
corresponded to 5542 genes, out of 11 769 full-
length cDNAs we identiﬁed in this study. As our
cDNA libraries were constructed using RNAs derived
from more than 100 different types of tissues and
cells, we therefore used the 50-EST data for analyzing
gene expression. We next analyzed gene expression
proﬁles of Type A1 cDNAs containing the FEV diversity
and found that the FEVs of 261 cDNAs, which corre-
spond to 155 genes, showed speciﬁc expression
patterns that were different from those already
obtained for the genes with alternative TSSs
(Table 3). Thus, like the genes with alternative TSSs,
the expression patterns of the genes with FEVs likely
depended on the tissue and condition.
Consequently, we found genes producing multiple
protein-coding transcripts by AS.
3.5. Analysis of expression patterns of tissue-speciﬁc
expressed genes
We quantiﬁed tissue-speciﬁc expressions of 13 out
of 261 selected cDNAs by real-time PCR (Fig. 3).
Results of our analysis especially suggested that
there was a strong relationship between the tissue-
speciﬁc expression and diversity of gene function or
disease. We compared the expression proﬁle of a
speciﬁc gene by utilizing the TSS identiﬁed in this
study with that of the same gene in which a previously
identiﬁed TSS was utilized for expression. These results
are summarized in Supplementary Table S6 and are
discussed below in more detail.
First example, FGF13 is a gene that belongs to the
FGF family and is believed to play roles in cell proli-
feration and differentiation, and also in neuronal
differentiation.
28,29 FLJ57884 and FLJ57068 cDNAs
exhibited different ORF regions as a result of FEV and
were splicing variants of the known FGF13 cDNA.
The TSSs we found in each one of them were
located upstream from the TSS of FGF13. Whereas
the known TSS of FGF13 was expressed highly in
both fetal and adult brains, the TSSs of both
FLJ57884 and FLJ57068 cDNAs were highly
expressed only in the fetal brain. Moreover, the TSS
of our FLJ57068 cDNA was also expressed highly in
the kidney cancer (Fig. 3A). Second example, OXR1
is one of the oxidation stress receptivity genes loca-
lized in mitochondria.
30 The TSS of known OXR1
was expressed at equal levels in various tissues. But
the TSS we identiﬁed in the FLJ56044 cDNA was
located upstream from the known TSS of OXR1 and
was highly expressed in brain, kidney cancer and
lung cancer (Fig. 3B). Thus, these results suggested
that these two genes were using different TSSs to
regulate their expression levels in the brain.
Moreover, our results also suggest that, for both
genes, only one of the TSSs was preferentially recog-
nized by the transcription machinery in the cancerous
tissue.
Third example, C6orf142 (chromosome 6 ORF
142) is a gene of an unknown function. The known
TSS of C6orf142 was highly expressed in the heart.
However, the TSS we identiﬁed in the FLJ58494
cDNA, which was located downstream from the pre-
viously identiﬁed TSS of C6orf142, was highly
expressed in both fetal and adult brains (Fig. 3C).
Table 2. Functional classiﬁcation of two types of splicing patterns
of 11 769 full-length cDNAs based on GO category analysis
Functional categorization
(GO: molecular function)
Number of matched cDNAs
Type A
(%)
Type B
(%)
Type
A þ B
Binding
Lipid binding 4 (14.3) 24 (85.7) 28
Tetrapyrrole binding 5 (18.5) 22 (81.5) 27
Neurotransmitter
binding
12 (50.0)* 12 (50.0) 24
Carbohydrate binding 4 (18.2) 18 (81.8) 22
Cofactor binding 3 (16.7) 15 (83.3) 18
Steroid binding 1 (10.0) 9 (90.0) 10
Catalytic activity
Helicase activity 4 (10.5) 34 (89.5) 38
Small protein activating
enzyme activity
2 (18.2) 9 (81.8) 11
Cyclase activity 6 (54.5)* 5 (45.5) 11
Enzyme regulator activity
GTPase regulator activity 31 (68.9)* 14 (31.1) 45
Enzyme activator activity 6 (50.0)* 6 (50.0) 12
Structural molecule
activity
Structural constituent of
ribosome
1 (4.0) 24 (96.0) 25
Transporter activity
ATPase activity, coupled
to movement of
substances
23 (59.0)* 16 (41.0) 39
Electron transporter
activity
2 (13.3) 13 (86.7) 15
Total 1344 (32.0) 2862 (68.0) 4206
The ratio of Type A and Type B is 3:7 as shown by total. Total
is all the results of classiﬁcation in the category of molecular
function. If a protein was predicted to belong to two or
more categories, all categories were included for counting.
*Functional categories biased to Type A.
No. 6] Ai Wakamatsu et al. 377Table 3. Expressions of a selected list of 261 FEV-containing cDNAs (155 genes)
FLJ ID Speciﬁc
expression
Gene
symbol
FLJ ID Speciﬁc
expression
Gene symbol FLJ ID Speciﬁc
expression
Gene
symbol
FLJ ID Speciﬁc
expression
Gene symbol
FLJ50079 Brain NRK FLJ52319 Trachea GNE FLJ55043 FB, NT PDZRN3 FLJ57051 Brain Pld5
FLJ50162 Brain LARGE1 FLJ52354 Brain, NT CHRNB1_pre FLJ55050 Brain EPS15 FLJ57068 FB FGF13
FLJ50199 Brain ARHGEF6 FLJ52356 Testis ARMC4 FLJ55194 Brain Unknown FLJ57107 Brain, NT CHRNB1_pre
FLJ50365 Trachea CRISPLD1 FLJ52358 Testis TP73 FLJ55226 FB CHST10 FLJ57108 Brain SNAP91
FLJ50390 Brain GRIA1_pre FLJ52367 Testis IQGAP2 FLJ55256 Synovial TFEC FLJ57207 Im Unknown
FLJ50398 Testis IQGAP2 FLJ52368 Testis, Trachea ARMC4 FLJ55265 Im Unknown FLJ57232 Testis PRCP_pre
FLJ50459 Brain ETV1 FLJ52384 Im PTPN3 FLJ55281 Heart, Fetal heart SLC5A1 FLJ57269 Brain BTBD10
FLJ50460 Brain DLG4 FLJ52407 Testis CRB1_pre FLJ55284 FB, NT MAGI2 FLJ57290 Trachea CRISPLD1
FLJ50484 Brain SLC26A4 FLJ52427 Brain AMPD3 FLJ55338 FB CLASP1 FLJ57298 Brain RAPGEF4
FLJ50494 Brain ETV1 FLJ52435 Testis MARCH7 FLJ55344 Brain DYSF FLJ57302 Brain RAPGEF4
FLJ50523 Brain PEX5L FLJ52438 Brain RIMS1 FLJ55381 FB SLC44A5 FLJ57330 Brain APBB1
FLJ50526 Brain PEX5L FLJ52453 Testis AMPD3 FLJ55423 Placenta NRK FLJ57521 Tu PPFIBP2
FLJ50533 Brain SLC6A9 FLJ52496 Brain TSPAN5 FLJ55434 Testis POMGNT1 FLJ57884 FB FGF13
FLJ50539 Brain, NT DCAMKL1 FLJ52520 FB EOMES FLJ55460 Brain SEMA5B_pre FLJ57888 Brain SGCB
FLJ50557 Brain MAP7 FLJ52731 Brain SPRED2 FLJ55461 NT KLHL13 FLJ57953 Brain STAU
FLJ50577 FB DLG4 FLJ52750 Brain ARHGEF7 FLJ55481 NT RGMA_pre FLJ58008 Brain PPP2R2B
FLJ50619 NT ELAVL4 FLJ52810 Testis GABRB3_pre FLJ55495 Testis PCYT2 FLJ58099 Brain CLTCL1
FLJ50623 Brain, NT DCAMKL1 FLJ53109 Testis PPP2R5E FLJ55504 Testis KLHL13 FLJ58366 Brain RIMS1
FLJ50641 Brain ETV1 FLJ53114 Testis NCAM2_pre FLJ55514 Brain, Tu EGFR_pre FLJ58368 Brain RAPGEF4
FLJ50646 FB DLG4 FLJ53167 NT CUL4B FLJ55516 Tu LIMS1 FLJ58494 Brain Unknown
FLJ50725 Testis ATPAF1 FLJ53184 Brain PPFIA2 FLJ55607 Brain, Trachea HDAC9 FLJ58753 Brain ARHGEF3
FLJ50745 Testis CCNA1 FLJ53222 FB MLLT3 FLJ55622 Testis MMRN1_pre FLJ58755 Brain CHN2
FLJ50761 Brain LRIG1_pre FLJ53242 Testis CLASP1 FLJ55627 Testis MOV10L1 FLJ58966 Im RAB37
FLJ50773 Brain CALB1 FLJ53247 Testis IDE FLJ55628 Testis LOXHD1 FLJ59303 Brain DOCK4
FLJ50776 Brain ARHGEF6 FLJ53252 Testis CDH2_pre FLJ55641 Brain, NT JARID2 FLJ59333 Tu RARG
FLJ50810 FB, NT MAGI2 FLJ53320 Brain DLGAP1 FLJ55662 Im FGR FLJ59338 Tu RARG
FLJ50844 Brain WARS2_pre FLJ53324 Brain TJP2 FLJ55664 Testis NTRK3_pre FLJ59345 Brain PPFIA2
FLJ50917 Testis PCCB_pre FLJ53330 Brain, NT EXOC4 FLJ55778 Brain CLASP1 FLJ59425 Placenta SH3KBP1
FLJ50956 Brain RAPGEF4 FLJ53518 Testis POMGNT1 FLJ55834 Brain, NT FGF11 FLJ59496 Brain CHN2
FLJ50959 Brain RAPGEF4 FLJ53578 Brain Rims1 FLJ55856 Testis ARHGEF3 FLJ59502 Brain PPFIA2
FLJ50961 Brain TMEM16C FLJ53606 NT AKT1 FLJ55859 Testis ST7L FLJ59511 Brain GRIA1_pre
FLJ50989 FB EOMES FLJ53680 Testis KIF2C FLJ55865 Im SLC43A2 FLJ59545 Brain EML2
FLJ51025 Kidney NOX4 FLJ53829 Brain APBB1 FLJ55903 FB GPR161 FLJ59625 Brain ARHGEF7
FLJ51027 Kidney NOX4 FLJ53875 Brain APBB1 FLJ55905 Im FGD4 FLJ59641 Testis PPFIA2
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,FLJ51073 FB EOMES FLJ53929 Im PTPN4 FLJ55906 Testis KIFC3 FLJ59648 Im DYSF
FLJ51155 Testis Unknown FLJ53980 Brain PPM1F FLJ55918 Brain EML2 FLJ59678 Brain PEX5L
FLJ51157 Testis HDAC4 FLJ53990 Brain GABRB3_pre FLJ55961 Brain GRM4_pre FLJ59684 Brain PLEKHG5
FLJ51174 Im HDAC4 FLJ53997 Brain CTNNA2 FLJ55997 Brain CPNE6 FLJ59710 Brain MCF2
FLJ51177 Im HDAC4 FLJ53999 Brain GAB1 FLJ56033 Testis Unknown FLJ59717 FB TBR1
FLJ51210 Brain KIFC3 FLJ54008 Brain TPCN1 FLJ56036 Tu KIFC3 FLJ59769 Im PLEKHG5
FLJ51383 Testis PPP2R5A FLJ54011 Brain PPFIA2 FLJ56037 Testis, Prostate CUL2 FLJ59799 Testis CTNNA2
FLJ51528 Im BTNL8_pre FLJ54016 Testis DIP13B FLJ56038 Small intestine Unknown FLJ59802 Testis ADCY5
FLJ51566 Brain PDK1 FLJ54093 Brain GPHN FLJ56044 Brain OXR1 FLJ59806 Im HDAC4
FLJ51606 Trachea HABP2_pre FLJ54100 Brain CHN2 FLJ56093 Brain PTPRR_pre FLJ60503 Brain LARGE1
FLJ51663 Testis CPS1_pre FLJ54331 Brain, Osteoclast Unknown FLJ56095 Brain KLHL13 FLJ60665 Tu SLC44A5
FLJ51675 Brain ETV1 FLJ54394 Testis CRB1_pre FLJ56110 FB GOLSYN FLJ60667 Tu SLC44A5
FLJ51685 Testis MCF2 FLJ54513 Testis WDR59 FLJ56116 FB APLP1 FLJ60693 FB PHF21B
FLJ51695 Im TP74 FLJ54541 FB EXOC4 FLJ56136 NT SLC2A14 FLJ60998 Testis INPP4B
FLJ51706 Testis RAPGEF4 FLJ54577 NT HDAC9 FLJ56137 Im Unknown FLJ61124 Brain RAB37
FLJ51734 Uterus TMEM16C FLJ54580 NT HDAC9 FLJ56142 NT AMOTL2 FLJ61133 FB EXOC4
FLJ51737 Brain ARHGEF6 FLJ54612 Brain SH3KBP1 FLJ56148 Brain PLEKHG5 FLJ61370 FB SNCAIP
FLJ51769 Testis IQGAP2 FLJ54642 Brain APBB1 FLJ56167 Testis KLHL12 FLJ61443 Testis LARGE1
FLJ51805 Brain RIMS2 FLJ54658 Brain LSAMP_pre FLJ56226 NT SNCAIP FLJ61560 Trachea TJP2
FLJ51859 Brain APBB1 FLJ54672 Brain DOCK4 FLJ56370 Testis, Prostate FKBP8 FLJ61674 Brain PEX5L
FLJ51873 Brain, NT AGPS_pre FLJ54673 Brain Unknown FLJ56376 Brain MTMR1 FLJ61679 Brain APBB1
FLJ51910 FB GTPBP3 FLJ54674 Brain TPCN1 FLJ56411 Brain GRIA2_pre FLJ53199 Brain # NEDD4L
FLJ51934 Im AOAH_pre FLJ54690 Brain BACE1_pre FLJ56420 Testis DNPEP FLJ59993 Brain # RIMS1
FLJ51957 NT ELAVL4 FLJ54693 Brain BACE1_pre FLJ56452 Brain EML2 FLJ55591 Brain # ARHGEF3
FLJ51977 Brain Unknown FLJ54702 Brain DLGAP1 FLJ56634 Brain GRM4_pre FLJ56152 Brain # ARHGEF7
FLJ52027 Testis ATPAF1 FLJ54724 FB DLG2 FLJ56895 Testis EML2 FLJ58411 FB # CACNB3
FLJ52034 Im Unknown FLJ54738 Brain PDZRN3 FLJ56912 Uterus FBLN2_pre FLJ58949 FB # CACNB3
FLJ52037 Im GRAP2 FLJ54742 Testis Slmap FLJ56913 Placenta, Uterus FBLN2 FLJ57810 Tu # A2ML1
FLJ52039 Im GRAP2 FLJ54746 NT PDZRN3 FLJ56957 Brain TMEM16C FLJ53545 Tu # RARG
FLJ52041 Im Unknown FLJ54751 NT SUV420H1 FLJ56961 Brain CLTCL1
FLJ52042 Im GRAP2 FLJ54906 Trachea TMC5 FLJ56973 Brain TMEM16C
FLJ52288 Testis ARMC4 FLJ54987 FB PHF21B FLJ56979 Brain MYRIP
We analyzed expression proﬁles of the ﬁrst exons of  1.5 million 5’-ESTs constructed by the oligo-capping method. From this analysis, we selected 261 full-length
cDNAs based on the expression levels of their FEVs in speciﬁc tissues. Expression levels of cDNAs indicated without any label and with a ‘#’ label were high and low,
respectively, in the respective tissues.
*NT: NT2 cell induced by retinoic acid; FB, fetal brain; Im, immune tissues; Tu, tumor tissues; pre, precursor; unknown, function unknown.
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9Fourth example, PLD5 is one of the phospholipid-
splitting enzymes presumably involved in the intra-
cellular signaling.
31 Although the known TSS of
PLD5 was expressed equally in various tissues, the
TSS we identiﬁed in the FLJ57051 cDNA, which was
located downstream of the previously identiﬁed TSS
of PLD5, was highly expressed in the brain (Fig. 3D).
Fifth example, SPRED2 is a Ras inhibitory factor
belonging to the Sprouty/Spred family.
32 The TSS we
identiﬁed in the FLJ52731 cDNA, which was located
downstream from the known TSS of SPRED2, was
expressed highly in the brain (Supplementary Table
S6). Sixth example, SEMA5B is a nerve guidance
factor which is involved in organogenesis, angiogen-
esis and oncogenesis.
33 The TSS we identiﬁed in the
FLJ55460 cDNA, which was located downstream
from the known TSS of SEMA5B, also was expressed
highly in the brain (Supplementary Table S6).
Seventh example, CACNB3 is a calcium channel
beta-3 subunit, which is involved in modifying sym-
pathetic nervous system, olfaction and control of
blood pressure.
34 Although the known TSS of
CACNB3 was expressed highly in both fetal and
adult brains, the newly identiﬁed TSSs of FLJ58949
and FLJ58411 cDNAs, both of which were located
downstream from the known TSS of CACNB3, were
expressed at a low level in the brain (Supplementary
Table S6). These cDNAs exhibited different ORF
regions as a result of AS. Eighth example, BACE1 is a
peptide hydrolase that cleaves the amyloid precursor
protein and is one of the factors involved in
Alzheimer’s disease.
35 The known TSS of BACE1 was
expressed equally in various tissues. However, the
TSS we identiﬁed in the FLJ54690 cDNA, which was
located downstream from the known TSS of BACE1,
was expressed highly in the brain (Supplementary
Table S6). Thus, these six genes regulated their
expression levels in the brain using a speciﬁc TSS in
each gene.
Ninth example, FGD4 is a gene that seemed to be
involved in the regulation of the actin in the cytoske-
leton and cell shape and also have various roles in pro-
liferation, differentiation, transcriptional regulation
and development.
36 The known TSS of FGD4 was
highly expressed in the nervous system tissues such
as brain, spinal cord and testis. However, the TSS we
Figure 3. Quantitative evaluation of selected genes by real-time PCR. Expression levels of the ﬁrst exon regions of the selected genes were
analyzed by real-time PCR. The data were normalized with respect to that of the human GAPDH as described in the Materials and
methods section. The expression levels of genes were represented in log10 base. Expression levels of cDNAs labeled ‘$$’ represent the
very low expression level or undetected. (A) FGF13, (B) OXR1, (C) C6orf142, (D) PLD5, (E) FGD4, (F) C6orf32. BW, brain, whole; BC,
brain, cerebellum; BF, fetal brain; SP, spleen; BM, bone marrow; TH, thymus; OV, ovary; PR, prostate; UT, uterus; MT, mixture of tumor
human tissues; MN, control, mixture of normal human tissues; KT, kidney tumor; LT, lung tumor.
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downstream from the known TSS of FGD4, was
highly expressed in the immune system tissues such
as bone marrow and spleen (Fig. 3E). Tenth
example, C6orf32 is a gene of unknown function
whose expression level increased during the myoblast
differentiation of the embryo.
37 FLJ56038 and
FLJ56137 cDNAs exhibited different ORF regions as
a result of FEV and were splicing variants of the
known C6orf32 cDNA. The known TSS of C6orf32
was expressed at equal levels in various tissues.
However, the TSSs we found in FLJ56038 and
FLJ56137 cDNAs were located upstream of the
known TSS of C6orf32, and both of these newly ident-
iﬁed TSSs were highly expressed in the immune
system tissues such as bone marrow, spleen and
thymus (Fig. 3F). Eleventh example, PTPN4 is a gene
belonging to the PTP (tyrosine escape phosphoric
acid enzyme) family that works as a transmitter and
controls various cellular processes like cell prolifer-
ation, differentiation, mitotic cycle and oncogen-
esis.
38 The known TSS of PTPN4 was highly
expressed in the brain, but the TSS we identiﬁed in
the FLJ53929 cDNA, which was located downstream
from the known TSS of TPN4, was highly expressed
in the immune system tissues such as bone marrow
and spleen (Supplementary Table S6). Twelfth
example, BTNL8 is one of the butyrophilin-like pro-
teins and seemed to be involved in conferring immu-
nity.
39 The known TSS of BTNL8 was found to be
expressed at equal levels in various tissues. However,
the TSS we identiﬁed in the FLJ51528 cDNA, which
was located downstream from the known TSS of
BTNL8, was highly expressed in the lung and thymus
(Supplementary Table S6). Thus, it seems that these
four genes regulated their expression levels in the
immune system tissues by using speciﬁc TSSs.
Thirteenth example, AKT1 is a gene involved in
apoptosis and neuronal differentiation and also may
have a role in schizophrenia, especially in the neuro-
transmission system.
40 The TSS we identiﬁed in the
FLJ53606 cDNA, which was located downstream
from the known TSS of AKT, was highly expressed in
the retinoic acid-induced NT2 cells (Supplementary
Table S6). Thus, this gene uses a speciﬁc TSS during
the neuronal differentiation.
Thus, among the newly identiﬁed genes we have
analyzed in this study, the TSSs of a number of these
genes revealed speciﬁc expression patterns. These
results suggest that a single gene could use alternative
TSS for tissue-speciﬁc transcription. We also found a
close relationship between the predicted function of
a gene and its tissue-speciﬁc expression. Thus, our
results suggest a strong correlation between the
mRNA diversity and function of a gene.
3.6. Construction and use of the FLJ Human cDNA
Database
We constructed the FLJ Human cDNA Database ver.
3.0 (http://ﬂj.lifesciencedb.jp) based on the results of
our analysis of variable protein-coding transcripts pro-
duced from a gene by AS. A detailed description of our
DB is available at the DB website. The DB graphically
displays mapping of all the full-length cDNAs in the
human genome and their ORF regions and thus pro-
vides a lot of useful information on the mRNA diver-
sity. Moreover, the DB not only contain sequence
information on full-length human cDNAs but also
contain sequence information on a huge number of
human ESTs generated using the oligo-capping
method, allowing us to obtain useful information on
ESTs mapped on the same genome locus. Because
the average length of our EST sequences was  500
bases, the diversity of mRNAs produced as a result of
AS could be efﬁciently analyzed by using this infor-
mation. Because we were able to accurately identify
TSSs using our 50-EST data, we believe that they
could be used to understand the relationship
between the variable utilization of TSSs and biological
functions of genes. Moreover, one could analyze the
expression proﬁles of the transcriptional region of
genes using the data from our high accuracy 50-EST
sequences, although in some cases the results
might be different from those obtained using the
30-EST data.
Despite these useful features, our database special-
izes on 50-end sequences, and therefore these data are
not suitable for predicting AS in the C-terminal end.
Then, a lot of AS-related information still remain to
be extracted from our 1.4 million cDNA resources as
all of them were not sequenced to completion.
Because our cDNA resources are mostly full-length
cDNAs including the TSS and the polyA site, complete
sequencing of these cDNA clones will add to our
understanding of the mRNA diversity. In addition,
every full-length sequenced FLJ cDNAs is available
from the National Institute of Technology and
Evaluation (http://www.nite.go.jp/). We will continue
to add new information on our resources to our data-
base, and these resources will be very useful in the
analysis of gene functions.
Because our interest was on the mRNAs with ORF
regions different from those of already known mRNAs,
we stopped sequencing the cDNA once we found that
thepredictedORFregionofthetranscriptwasnotdiffer-
ent from the known mRNA (for instance, where the
alternative TSS only existed in the 50-untranslated
region). We, however, found that there is a tissue speci-
ﬁcity in the expression patterns of these genes where
the variation in TSS existed in the 50-untranslated
region (results not shown). Collectively, these results
No. 6] Ai Wakamatsu et al. 381suggest that depending on the situation and environ-
ment, the transcription machinery utilizes alternative
TSS to regulate the expression of a transcript, even
when the translated protein is same. These results are
also included in our DB. We also did not complete
sequencing the clones for which we were unable to
predict the ORF regions of their mRNAs. However, we
have also included these clones in the DB with the
belief that one could obtain some new and useful infor-
mation by analyzing these clones.
We discovered a lot of genes had mRNA diversity
due to, for example, FEVs. We also found a lot of
tissue-speciﬁc splicing patterns. Especially, in the
case of FEVs that we analyzed, genes used different
regions of the genome loci as the ﬁrst exon, which
seemed to be dependent on the tissue and its con-
dition. We also discovered genes, the TSSs of which
were located further away on the same genome
locus of the gene. In these cases, there exists a high
possibility that their transcription is controlled by
individual transcription factors. As the mechanisms
for controlling the transcription are closely related
to the function, by understanding these mechanisms
one could be able to artiﬁcially control the expression
of an appropriate transcript in the future.
In this study, we have identiﬁed multiple transcripts
producing genes, and we believe that each one of
these genes is transcribed into an appropriate tran-
script according to the need and circumstance. Now,
it will be important to know whether there is any cor-
relation between the expression of one of the tran-
scripts produced by a gene and a disease. For
example, in the case of transcripts containing FEVs,
which we analyzed in detail, only the ﬁrst exon
regions were different from the other previously
characterized transcripts. Since the ﬁrst exon regions
of these transcripts are unique, it is possible to dis-
tinguish them easily from the other transcripts. It
may be possible to control the expression of a speciﬁc
mRNA from a group of mRNAs transcribed from a
gene by targeting the ﬁrst exon. As we accumulate
more information on mRNA diversity of genes using
approaches similar to what we have described in this
study, we might be able to identify candidate genes
as novel targets for the development of drugs with
lower side effects.
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